The European Center for the Study of Diabètes (CEED), created in 1991 and based in Strasbourg is a translational research structure or associate researchers and doctors to meet the laboratory research to question of health care teams and patient’s expectations. CeeD is the BIOSID project coordinator and is responsible to study the needs of pancreatic islets in terms of viabilities and functions, and that, in animal models developed internally.
The Laboratory of experimental surgery at UCL in Brussels has for the past 20 years, primarily focused on the field of transplantation immunology on large sizes animals. The laboratory has a 600m² aniomal house for animal testing, post-operative care and monitoring of transplanted animals. As part of its collaborationwith Defymed, UCL provides a pre–clinical model “in vivo”. This is an important step in the development of MAILPAN before clinical trials on human.
CHU of Montpellier has in the last 20 years developed a specific expertise in patients with Type 1 diabetes. More precisely, in portablesystems implantable, allowing a constant supply of insulin as well as glucose monitoring services. CHU is involved in the isolation of human pancreatic islets ans is one of the centers where will be conducted the clinical trials on the MAILPAN.
The Nuffield Department of Surgical Sciences (NDS) at Oxford, is a center that combines clinical care, research and education on diabetes and endocrine and metabolic diseases. NDS was one of the first research centers in the field of human pancreatic islet transplantation in the last 30 years. This center contributes to the project by the isolation of pancreatic islets and in improving the viability and islet function when implanted in the device. NDS will implant the MAILPAN in parallel to CHU in some of the patients.
Endocells is a french company, based in Paris and specializes in the development of technologies to provide an unlimited source of cells of human origin with endocrine properties. The first focus of Endocells relates to insulin-secreting cells to treat type 1 diabetes. As part of its collaboration with Defymed, Endocells provides insulin-secreting cells for testing in MAILPAN animal models. This, in order to test their functions and safety once encapsulated.
AvantiCell (ACS) is a biotechnology SME based in Scotland (UK), which specializes in cell culture technologies and in the formulation of culture media, depending on the type and needs of the cells, and the prouction large-scale analyzes. As part of its partnership with Defymed, ACS will test different culture media to define what would be the most suitable for cell survival in the MAILPAN.
MICROMECHA in Metz, SAS is established in 2012 which is focused on the development of micromachines and thermomechanical tests. These micromachines include mechanics, but also a control box and software enabling to carry different of stresses. MICROMECHA’s contribution is to design a 3D michromachine capable of mimicking the stresses of the MAILPAN will undergo once implanted.
Nimesis Technololgy is an SME created in 2008 and whose core business application development using the Shape Memory Alloys. Its key activity including the biomedical field as well as well as some high-technology sectors such as space, defense or luxury Watch. Nimesis is now considered one of the greatest European specialists in the field of smart materials. In his collaboration with Defymed, Nimesis will analyze the MAILPAN on complex tests benches which would mimic his behavior once implanted.
ARTS, privtely governed is specialized in the characterization of microstructures and in situ mechanical testing of complex poloymers. As part of its collaboration with Defymed, ARTS is responsible of the study of the mechanical strength of MAILPAN on benches tests until breaking or in situ, under an electron microscope.
Transvie Medical, a spin-off SME from the surgery school of Nancy-Lorraine, specializes in the preclinical validation of medical devices as waell as various therapeutic drugs with international collaborations, both in the public and private domains. Transvie Medical works on the mechanical validation of MAILPAN in animal models associated with advanced imaging.
The institute Jean Lamour, which combines the three scientific universities of Lorraine CNRS, will also examine the strength of MAILPAN before or after explantation in the animal models, on existing test benches under normal conditions or after aging.